TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33544337

Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg once daily)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Comparator EGFR TKI (gefitinib 250 mg once daily or erlotinib)
Number of subjects: 136
Study: 33275096

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin alone
Number of subjects: 1858

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin plus graduated compression stockings
Number of subjects: 1858
Study: 36455143

Group type: EXPERIMENTAL
Intervention: HRV biofeedback
Number of subjects: 60
Study: 34389772

Group type: EXPERIMENTAL
Intervention: Decompressive hemicraniectomy (DHC)
Number of subjects: 95
Study: 36368598

Group type: EXPERIMENTAL
Intervention: Obeticholic Acid
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 33791991

Group type: EXPERIMENTAL
Intervention: Game Changers intervention
Number of subjects: 98
Study: 32053630

Group type: EXPERIMENTAL
Intervention: Moderate NPK treatment (50 kg N + 10 kg P + 50 kg K /ha)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High NPK treatment (100 kg N + 25 kg P + 100 kg K /ha)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Potassium only treatment (50 kg K/ha)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no fertiliser applied)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NPK fertiliser application
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NPK fertiliser application with corrected soil nutrient deficiencies
Number of subjects: 0
Study: 35776034

Group type: EXPERIMENTAL
Intervention: Quercetin-containing supplement (200 mg daily for 4 weeks)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 66
Study: 35383823

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (16,800 IU vitamin D3 once a week for 1 year)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (16,800 IU vitamin D3 once a week for 1 year) in subgroup with 25(OH)D concentrations of 15-25 nmol/L (n=31)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo in subgroup with 25(OH)D concentrations of 15-25 nmol/L (n=31)
Number of subjects: 155
Study: 32879147

Group type: EXPERIMENTAL
Intervention: Recombinant human soluble thrombomodulin (rhTM)
Number of subjects: 2865

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2865
Study: 34716636

Group type: EXPERIMENTAL
Intervention: Neurolinguistic Programming training group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard training group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study: 34956849

Group type: EXPERIMENTAL
Intervention: Structured education on TB-DM combined with clinical monitoring and medication adjustment
Number of subjects: 150

Group type: COMPARATOR
Intervention: Routine care (control arm)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Structured education on TB-DM
Number of subjects: 150
Study: 34166100

Group type: EXPERIMENTAL
Intervention: Digital Cognitive Task Analysis (CTA) tool
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (equipment instruction manual)
Number of subjects: 18
Study: 36442202

Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Games Training (CCT)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Web-based crossword puzzles (Control)
Number of subjects: 107
Study: 33472389

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 99

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 99

Group type: COMPARATOR
Intervention: Clozapine vs Haloperidol in patients with conduct disorder
Number of subjects: 99

Group type: COMPARATOR
Intervention: Clozapine vs Haloperidol in patients without conduct disorder
Number of subjects: 99

Group type: COMPARATOR
Intervention: Olanzapine vs Haloperidol in patients with conduct disorder
Number of subjects: 99
Study: 35258802

Group type: EXPERIMENTAL
Intervention: Intensive, multicomponent word reading and reading comprehension intervention for 2 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Business as usual (BaU)
Number of subjects: 0
Study: 32378932

Group type: EXPERIMENTAL
Intervention: Online intervention for alcohol use and PTSD (details on dosage and duration not available)
Number of subjects: 366
Study: 36397390

Group type: EXPERIMENTAL
Intervention: Midazolam 0.06 mg/kg (M2)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Midazolam co-induction
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 102
Study: 34462198

Group type: EXPERIMENTAL
Intervention: Gatekeeper-referral
Number of subjects: 197

Group type: COMPARATOR
Intervention: Self-referral
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Referral by medical practitioners
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Self-initiated contact
Number of subjects: 197
Study: 33768205

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 33356547

Group type: EXPERIMENTAL
Intervention: Deterra Drug Deactivation System deactivation pouches
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard opioid disposal instructions
Number of subjects: 75
Study: 33831566

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) supplementation (12.4 mmol NO3? per day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nitrate-depleted BR (placebo)
Number of subjects: 12
Study: 36197494

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study: 33499754

Group type: EXPERIMENTAL
Intervention: modified directly administered antiretroviral therapy (mDAART)
Number of subjects: 34

Group type: COMPARATOR
Intervention: standard of care
Number of subjects: 34
Study: 34996695

Group type: EXPERIMENTAL
Intervention: Active tDCS intervention
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 7
Study: 34673536

Group type: EXPERIMENTAL
Intervention: Supervised high-intensity interval training (SG)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Self-administered high-intensity interval training guided by smartphone app (AG)
Number of subjects: 40
Study: 32251068

Group type: EXPERIMENTAL
Intervention: Self-reported progression assessment (aggregate cluster of questions)
Number of subjects: 0
Study: 34766589

Group type: EXPERIMENTAL
Intervention: 2000 IU/day of oral cholecalciferol (vitamin D)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 40
Study: 36120873

Group type: EXPERIMENTAL
Intervention: Aging Mastery Program (AMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 32841433

Group type: EXPERIMENTAL
Intervention: 75 mg pycnogenol taken orally twice a day for 60 days
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo taken orally twice a day for 60 days
Number of subjects: 44
Study: 616769481

Group type: COMPARATOR
Intervention: Lidocaine 20 mg IV
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lidocaine 20 mg and Ketorolac 10 mg IV
Number of subjects: 90
Study: 33482699

Group type: EXPERIMENTAL
Intervention: vonapanitase
Number of subjects: 603

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 603
Study: 36247802

Group type: EXPERIMENTAL
Intervention: Exercise training (2/3 aerobic, high-intensity interval training sessions per week supervised by personal trainers)
Number of subjects: 1560

Group type: EXPERIMENTAL
Intervention: Psychological support (1 session per week at a local cancer support centre)
Number of subjects: 1560

Group type: EXPERIMENTAL
Intervention: Combined exercise and psychological support
Number of subjects: 1560

Group type: COMPARATOR
Intervention: Usual pre-operative care (control group)
Number of subjects: 1560
Study: 32203986

Group type: EXPERIMENTAL
Intervention: Two-channel water exchange colonoscopy
Number of subjects: 120

Group type: COMPARATOR
Intervention: One-channel water exchange colonoscopy
Number of subjects: 120
Study: 35738656

Group type: EXPERIMENTAL
Intervention: HMB-enriched nutritional supplements (65 g/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 32051513

Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD) for 6 weeks
Number of subjects: 77

Group type: COMPARATOR
Intervention: Gluten challenge (double-blind placebo controlled)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 77
Study: 34128780

Group type: EXPERIMENTAL
Intervention: Personalized Cognitive Stimulation (PCS) program for 10 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no PCS program)
Number of subjects: 50
Study: 33092986

Group type: EXPERIMENTAL
Intervention: Low-fidelity otoscopy simulation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Traditional teaching methods (Control)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Satisfaction questionnaire
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Recommendation for curriculum inclusion
Number of subjects: 200
Study: 33611847

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 724

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study: 32211776

Group type: EXPERIMENTAL
Intervention: Negative HBV RNA and HBcrAg < 4 log10 U/mL at end of treatment (EOT)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Positive HBV RNA and HBcrAg ≥ 4 log10 U/mL at EOT
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Negative HBV RNA and HBcrAg < 4 log10 U/mL at EOT
Number of subjects: 186

Group type: COMPARATOR
Intervention: Entecavir or tenofovir before discontinuation (validation cohort)
Number of subjects: 186
Study: 36134780

Group type: EXPERIMENTAL
Intervention: Humanized body weight check
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional body weight check
Number of subjects: 30
Study: 35196064

Group type: EXPERIMENTAL
Intervention: Financial reimbursement program (FRP) with follow-up telephone call
Number of subjects: 132

Group type: COMPARATOR
Intervention: Usual care (no follow-up)
Number of subjects: 132
Study: 33991482

Group type: EXPERIMENTAL
Intervention: Personal benefit information
Number of subjects: 15014

Group type: EXPERIMENTAL
Intervention: Safety concerns information
Number of subjects: 15014

Group type: EXPERIMENTAL
Intervention: Combination of all information
Number of subjects: 15014

Group type: COMPARATOR
Intervention: Control condition (safety and effectiveness statement from NHS)
Number of subjects: 15014
Study: 35745211

Group type: EXPERIMENTAL
Intervention: Micronized 2S-Hesperidin (M2SH)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Micronized Hesperidin epimeric mixture (MHEM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hesperidin epimeric mixture (HEM)
Number of subjects: 30
Study: 33938939

Group type: EXPERIMENTAL
Intervention: Infant weight-for-age z score at 12 months of age
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Rapid weight gain from birth to 24 months of age
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Rapid weight gain from birth to 3 months of age
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Length-related indicators during early life
Number of subjects: 294
Study: 32549090

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.045% lotion
Number of subjects: 1614

Group type: COMPARATOR
Intervention: Vehicle lotion
Number of subjects: 1614
Study: 35307055

Group type: EXPERIMENTAL
Intervention: Observation group (IVCV and Pcv-aCO2 monitoring)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (EGDT strategy)
Number of subjects: 80
Study: 34624047

Group type: EXPERIMENTAL
Intervention: Lifestyle medicine group (LM group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Care-as-usual group (CAU group)
Number of subjects: 31
Study: 32344285

Group type: EXPERIMENTAL
Intervention: Thyroid hormone administration (levothyroxine and liothyronine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35312970

Group type: EXPERIMENTAL
Intervention: Combination therapy with luseogliflozin 2.5 mg once daily and semaglutide 0.5 mg once per week
Number of subjects: 60

Group type: COMPARATOR
Intervention: Monotherapy with semaglutide
Number of subjects: 60
Study: 34796735

Group type: EXPERIMENTAL
Intervention: Electrocoagulation tuboplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continued medical therapy
Number of subjects: 0
Study: 32826450

Group type: EXPERIMENTAL
Intervention: Thin-strut drug-eluting stent (DES)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Thick-strut drug-eluting stent (DES)
Number of subjects: 50
Study: 33225901

Group type: EXPERIMENTAL
Intervention: FDA-approved immune checkpoint inhibitors (ICIs)
Number of subjects: 42
Study: 35714551

Group type: EXPERIMENTAL
Intervention: Methylphenidate (continued treatment for 7 weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (gradual withdrawal from methylphenidate for 7 weeks)
Number of subjects: 63
Study: 33270526

Group type: EXPERIMENTAL
Intervention: Bayesian methods for statistical inference
Number of subjects: 0

Group type: COMPARATOR
Intervention: Frequentist statistical approaches
Number of subjects: 0
Study: 36396067

Group type: EXPERIMENTAL
Intervention: Coin2Dose intervention for 12 weeks followed by a 12-week maintenance period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 0
Study: 34929355

Group type: EXPERIMENTAL
Intervention: Wii therapy (interactive gaming, Nintendo Wii)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 40
Study: 32915060

Group type: EXPERIMENTAL
Intervention: Robotic left pancreatectomy (RLP)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Laparoscopic left pancreatectomy (LLP)
Number of subjects: 75
Study: 32187403

Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion after exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo ingestion after exercise
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo ingestion
Number of subjects: 9
Study: 33052030

Group type: EXPERIMENTAL
Intervention: 6-week exercise group
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 35084243

Group type: EXPERIMENTAL
Intervention: Continuous moderate aerobic exercise (CE)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HIIE)
Number of subjects: 25
Study: 32572617

Group type: EXPERIMENTAL
Intervention: EX + PRO (30 min low-moderate-intensity treadmill walking followed by 20 g whey protein)
Number of subjects: 12

Group type: COMPARATOR
Intervention: EX (30 min low-moderate-intensity treadmill walking without whey protein)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CON (30 min rest)
Number of subjects: 12
Study: 33433386

Group type: EXPERIMENTAL
Intervention: FA-TiO2-Pc (low dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FA-TiO2-Pc (in vitro)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FA-TiO2-Pc
Number of subjects: 0
Study: 32466187

Group type: EXPERIMENTAL
Intervention: Continuous running exercise (CR) at 75% of VO2max for 25 min
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intermittent running exercise #1 (15/15) at 75% of VO2max for 50 min
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intermittent running exercise #2 (30/30) at 75% of VO2max for 50 min
Number of subjects: 13
Study: 32280656

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) applied to the surgical site after polyp removal.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control side (no PRP applied).
Number of subjects: 21
Study: 35236735

Group type: EXPERIMENTAL
Intervention: 5 mg olanzapine (OLZ) in combination with triple antiemetic therapy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo in combination with triple antiemetic therapy
Number of subjects: 500
Study: 33636373

Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham Dry Needling (sham-DN)
Number of subjects: 51
Study: 35998872

Group type: EXPERIMENTAL
Intervention: cathodal transcranial direct current stimulation (c‐tDCS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo stimulus (sham)
Number of subjects: 10
Study: 32202716

Group type: EXPERIMENTAL
Intervention: Xiao's 'xingnaofusu' needling and routine western medicine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine western medicine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Xiao's 'xingnaofusu' needling
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (routine western medicine)
Number of subjects: 50
Study: 35911085

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) <1 year after diagnosis
Number of subjects: 3608

Group type: EXPERIMENTAL
Intervention: Patients diagnosed in 2011
Number of subjects: 3608

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 3608

Group type: EXPERIMENTAL
Intervention: Gleason score ≥4 + 3
Number of subjects: 3608
Study: 32975189

Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream (Aldara) for up to 16 weeks
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: 0.15% podophyllotoxin cream (Warticon) for 4 weeks (extended to 16 weeks if warts persisted)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Quadrivalent human papillomavirus vaccine (Gardasil)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Saline control (placebo for HPV vaccine)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream (Aldara)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: 0.15% podophyllotoxin cream (Warticon)
Number of subjects: 503
Study: 36178015

Group type: EXPERIMENTAL
Intervention: Multifaceted optimization management (integration of usual care and traditional Chinese medicine treatment)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Multifaceted optimization management
Number of subjects: 256

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 256
Study: 34411629

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 34990772

Group type: EXPERIMENTAL
Intervention: L-Citrulline (6 g/day)
Number of subjects: 16
Study: 34878335

Group type: EXPERIMENTAL
Intervention: Flow cytometry-based antibiotic susceptibility testing (MICy)
Number of subjects: 6
Study: 32128859

Group type: EXPERIMENTAL
Intervention: Interferential stimulation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 33
Study: 36033363

Group type: EXPERIMENTAL
Intervention: Goal Management Training+ (GMT+)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Psychoeducation-control (Brain Health Workshop; BHW)
Number of subjects: 48
Study: 32624568

Group type: EXPERIMENTAL
Intervention: Exercise training (12-week strength and endurance combined training program)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (obese children not receiving exercise training)
Number of subjects: 39
Study: 33307192

Group type: EXPERIMENTAL
Intervention: Three-field lymphadenectomy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Two-field lymphadenectomy
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 400
Study: 33050913

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 80
Study: 35393772

Group type: EXPERIMENTAL
Intervention: Person-centred care intervention by trained nurses
Number of subjects: 84
Study: 33722880

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 13480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13480
Study: 32722955

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab
Number of subjects: 112

Group type: COMPARATOR
Intervention: Aflibercept
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Ranibizumab and aflibercept
Number of subjects: 112
Study: 35383975

Group type: EXPERIMENTAL
Intervention: Probiotic treatment (Lactobacillus and Bifidobacterium spp)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Oral metronidazole (MET)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 23
Study: 32702778

Group type: EXPERIMENTAL
Intervention: Dental Decision Simulation (DDSim)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not exposed to DDSim)
Number of subjects: 0
Study: 36454316

Group type: EXPERIMENTAL
Intervention: UINCARE Home+ (AR-based digital health care system)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Brochure-based home rehabilitation (Control)
Number of subjects: 100
Study: 33509192

Group type: EXPERIMENTAL
Intervention: ctDCS montage targeting dentate nuclei and anterior/posterior lobes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ctDCS montage targeting lower-limb representations (lobules VIIb-IX)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ctDCS montages
Number of subjects: 10
Study: 32694215

Group type: EXPERIMENTAL
Intervention: Albiglutide + optimized basal insulin glargine and lispro (dose reduced by 50% at randomization; lispro injections fully discontinued 4 weeks later)
Number of subjects: 814

Group type: COMPARATOR
Intervention: Lispro + optimized glargine
Number of subjects: 814
Study: 35196687

Group type: EXPERIMENTAL
Intervention: Three-dimensional printed models
Number of subjects: 432

Group type: COMPARATOR
Intervention: Two-dimensional pictures
Number of subjects: 432
Study: 34764501

Group type: EXPERIMENTAL
Intervention: Isobaric levobupivacaine (0.5%, 0.3-0.4 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isobaric ropivacaine (0.5%, 0.5 mg/kg)
Number of subjects: 60
Study: 33459945

Group type: EXPERIMENTAL
Intervention: Arterial occlusion to the left arm
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Venous stasis on the right arm
Number of subjects: 10
Study: 34087126

Group type: EXPERIMENTAL
Intervention: Daratumumab plus pomalidomide and dexamethasone
Number of subjects: 304

Group type: COMPARATOR
Intervention: Pomalidomide and dexamethasone
Number of subjects: 304
Study: 32125249

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BET)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 13